NCT03199534View on ClinicalTrials.gov

A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Pelvic PainDyspareuniaPelvic Floor Dysfunction
Interventions
DRUG

Botulinum toxin A 50u

Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.

DRUG

Botulinum toxin A 100u

Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.

DRUG

Botulinum toxin A 150u

Subject will receive injection of 150u Botulinum toxin A while anesthetized.

Trial Locations (1)

98034

EvergreenHealth Urology and Urogynecology Care, Kirkland

Sponsors

Lead Sponsor

EvergreenHealth
All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

lead

EvergreenHealth

OTHER

NCT03199534 - A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction | Biotech Hunter | Biotech Hunter